{
    "organizations": [],
    "uuid": "53a6446a89dbf1bed3cedff9b15ecc3e75372cd4",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-intellipharmaceutics-provides-oper/brief-intellipharmaceutics-provides-operational-update-idUSASB0C23J",
    "ord_in_thread": 0,
    "title": "BRIEF-Intellipharmaceutics Provides Operational Update",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 24 (Reuters) - Intellipharmaceutics International Inc :\n* INTELLIPHARMACEUTICS PROVIDES OPERATIONAL UPDATE * INTELLIPHARMACEUTICS - COMMERCIALIZATION OPPORTUNITIES FOR CO‘S PRODUCT HAVE BEEN “CHALLENGING IN U.S. DUE TO EXTREMELY COMPETITIVE COST ENVIRONMENT”\n* INTELLIPHARMACEUTICS INTERNATIONAL INC - CONTINUES EFFORTS TO IDENTIFY OPPORTUNITIES OVERSEAS, INCLUDING IN CHINA\n* INTELLIPHARMACEUTICS - RECENTLY HELD DISCUSSIONS IN CHINA TOWARD ESTABLISHING A PARTNERSHIP, HAS NOT ENTERED INTO ANY SUCH ARRANGEMENTS YET\n* INTELLIPHARMACEUTICS - EVALUATING PARTNERS FOR PHASE III STUDIES OF REGABATIN XR, EXPECT TO BEGIN STUDIES IN H2 2018\n* INTELLIPHARMACEUTICS - CONTINUES TO WORK WITH MALLINCKRODT AND PAR TO GAIN TRACTION IN U.S. FOR GENERIC SEROQUEL XR AND GENERIC FOCALIN XR\n* INTELLIPHARMACEUTICS - ANTICIPATE THAT NDA FOR OXYCODONE ER ABUSE-DETERRENT PROGRAM WILL BE RESUBMITTED TO FDA IN LATE SUMMER 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-24T21:43:00.000+02:00",
    "crawled": "2018-01-25T13:00:39.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "intellipharmaceutics",
        "international",
        "inc",
        "intellipharmaceutics",
        "provides",
        "operational",
        "update",
        "intellipharmaceutics",
        "commercialization",
        "opportunity",
        "co",
        "product",
        "challenging",
        "due",
        "extremely",
        "competitive",
        "cost",
        "environment",
        "intellipharmaceutics",
        "international",
        "inc",
        "continues",
        "effort",
        "identify",
        "opportunity",
        "overseas",
        "including",
        "china",
        "intellipharmaceutics",
        "recently",
        "held",
        "discussion",
        "china",
        "toward",
        "establishing",
        "partnership",
        "entered",
        "arrangement",
        "yet",
        "intellipharmaceutics",
        "evaluating",
        "partner",
        "phase",
        "iii",
        "study",
        "regabatin",
        "xr",
        "expect",
        "begin",
        "study",
        "h2",
        "intellipharmaceutics",
        "continues",
        "work",
        "mallinckrodt",
        "par",
        "gain",
        "traction",
        "generic",
        "seroquel",
        "xr",
        "generic",
        "focalin",
        "xr",
        "intellipharmaceutics",
        "anticipate",
        "nda",
        "oxycodone",
        "er",
        "program",
        "resubmitted",
        "fda",
        "late",
        "summer",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}